Human mesenchymal stromal cells primed with paclitaxel, apart from displaying anti-tumor activity, maintain their immune regulatory functions in vitro

Affiliations

¹ Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
² Department of Biomedical, Surgical, Dental Sciences, University of Milan, Italy.
³ UCV Neurobiology, IRCCS Neurological Institute, Carlo Besta, Milan, Italy.
⁴ Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy; University of Pavia, Pavia, Italy.

Comment

Antonella Conforti et al. Cytotherapy. 2014 Jun.

. 2014 Jun;16(6):868-70.

doi: 10.1016/j.jcyt.2014.01.414. Epub 2014 Mar 13.

¹ Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
² Department of Biomedical, Surgical, Dental Sciences, University of Milan, Italy.
³ UCV Neurobiology, IRCCS Neurological Institute, Carlo Besta, Milan, Italy.
⁴ Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy; University of Pavia, Pavia, Italy.

No abstract available

Keywords: anti-tumor effect; immune modulatory properties; mesenchymal stromal cells; paclitaxel.

Comment on

Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy.
Pessina A, Bonomi A, Coccè V, Invernici G, Navone S, Cavicchini L, Sisto F, Ferrari M, Viganò L, Locatelli A, Ciusani E, Cappelletti G, Cartelli D, Arnaldo C, Parati E, Marfia G, Pallini R, Falchetti ML, Alessandri G. Pessina A, et al. PLoS One. 2011;6(12):e28321. doi: 10.1371/journal.pone.0028321. Epub 2011 Dec 20. PLoS One. 2011. PMID: 22205945 Free PMC article.